Singapore gene therapy startup Nuevocor snags more funding

Biotech company pulls in another $11.6m from existing investors

20221104 gene

Singapore-based preclinical-stage biotech startup Nuevocor develops gene therapy for the treatment of cardiac diseases. (Photo by AP)

MARS W. MOSQUEDA JR., DealStreetAsia

CEBU, Philippines -- Nuevocor, a Singapore-based preclinical-stage biotech startup, has raised an additional $11.6 million in funding from existing investors, according to regulatory filings.

The filings with Singapore's Accounting and Corporate Regulatory Authority only reflect the equity funding received so far in a round, and the overall funding round could be larger or have other components such as debt. DealStreetAsia has reached out to Nuevocor for confirmation.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.